Kok, V.C.; Chen, Y.-C.; Chen, Y.-Y.; Su, Y.-C.; Ku, M.-C.; Kuo, J.-T.; Yoshida, G.J.
Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study. Cancers 2019, 11, 985.
https://doi.org/10.3390/cancers11070985
AMA Style
Kok VC, Chen Y-C, Chen Y-Y, Su Y-C, Ku M-C, Kuo J-T, Yoshida GJ.
Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study. Cancers. 2019; 11(7):985.
https://doi.org/10.3390/cancers11070985
Chicago/Turabian Style
Kok, Victor C., Yu-Ching Chen, Yang-Yuan Chen, Yu-Chieh Su, Ming-Chang Ku, Jung-Tsung Kuo, and Go J. Yoshida.
2019. "Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study" Cancers 11, no. 7: 985.
https://doi.org/10.3390/cancers11070985
APA Style
Kok, V. C., Chen, Y. -C., Chen, Y. -Y., Su, Y. -C., Ku, M. -C., Kuo, J. -T., & Yoshida, G. J.
(2019). Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study. Cancers, 11(7), 985.
https://doi.org/10.3390/cancers11070985